These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 17785949)

  • 1. Problems with registration-directed clinical trials for lung cancer in Japan.
    Sekine I; Nokihara H; Yamamoto N; Kunitoh H; Ohe Y; Saijo N; Tamura T
    Tohoku J Exp Med; 2007 Sep; 213(1):17-23. PubMed ID: 17785949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors that influence the eligibility of cases for inclusion in clinical trials. The Lung Cancer Chemotherapy Study Group of the Japan Clinical Oncology Group.
    Kasai T; Ohe Y; Nishio K; Kunitoh H; Tamura T; Sekine I; Kubota K; Yamamoto N; Nakamura Y; Shinkai T; Kodama T; Saijo N
    Jpn J Clin Oncol; 1998 Mar; 28(3):214-21. PubMed ID: 9614446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
    Adis International Ltd
    Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Current problems of early phase clinical trials for new anticancer agents in Japan].
    Nakagawa K; Fukuoka M
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):925-9. PubMed ID: 10897223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality evaluation of investigator-initiated trials using post-approval cancer drugs in Japan.
    Kondo S; Hosoi H; Itahashi K; Hashimoto J
    Cancer Sci; 2017 May; 108(5):995-999. PubMed ID: 28266163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
    Wolf M; Swaisland H; Averbuch S
    Clin Cancer Res; 2004 Jul; 10(14):4607-13. PubMed ID: 15269131
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The revision of Guidelines for Clinical Evaluation Methods of Anti-Cancer Drugs in Japan].
    Andoh M; Fujiwara Y; Shimada Y
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):1015-9. PubMed ID: 16878363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
    Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status and problems in clinical trial for new anticancer drug in Japan].
    Fukuoka M
    Gan To Kagaku Ryoho; 1996 Jan; 23(2):141-5. PubMed ID: 8611040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Current status and issues in clinical trials of anticancer agents].
    Kojima H
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Globalization of clinical trials].
    Akaza H; Fukuoka M; Ohtsu A; Usami M; Ikeda T; Aiba K; Isonishi S; Ohashi Y; Saijo N; Sone S; Tsukagoshi S; Tsuruo T; Kato M; Mikami O; Dong RP; von Euler M; Blackledge G; Stribling D
    Gan To Kagaku Ryoho; 2003 Apr; 30(4):555-65. PubMed ID: 12722692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Compliance with Good Clinical Practice in oncology registration trials in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Ann Oncol; 2011 Jun; 22(6):1451-1456. PubMed ID: 21119030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Phase II clinical trials in patients with lung cancer].
    Shinkai T; Saijo N
    Nihon Kyobu Shikkan Gakkai Zasshi; 1993 Dec; 31 Suppl():232-44. PubMed ID: 8007470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic response and potential pitfalls in phase I clinical trials of anticancer agents conducted in Japan.
    Itoh K; Sasaki Y; Miyata Y; Fujii H; Ohtsu T; Wakita H; Igarashi T; Abe K
    Cancer Chemother Pharmacol; 1994; 34(6):451-4. PubMed ID: 7923553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Marimastat: BB 2516, TA 2516.
    Drugs R D; 2003; 4(3):198-203. PubMed ID: 12757409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Improving the infrastructure for clinical trials in Japan].
    Nakano S
    Gan To Kagaku Ryoho; 1999 Jan; 26(2 Suppl):225-30. PubMed ID: 9987523
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Originality benefit and difficulty of clinical research in the West Japan Lung Cancer Group.
    Kawahara M; Ariyoshi Y; Fukuoka M; Furuse K
    Crit Rev Oncol Hematol; 2000 Oct; 36(1):9-12. PubMed ID: 10996519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanoma Vaccine--AVAX Technologies: DNP-VACC, M-Vax.
    BioDrugs; 2003; 17(1):69-72. PubMed ID: 12534322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.